Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Front Mol Biosci ; 9: 783669, 2022.
Article in English | MEDLINE | ID: mdl-35252348

ABSTRACT

Macrophage migration inhibitory factor (MIF) is an inflammatory protein with various non-overlapping functions. It is not only conserved in mammals, but it is found in parasites, fish, and plants. Human MIF is a homotrimer with an enzymatic cavity between two subunits with Pro1 as a catalytic base, activates the receptors CD74, CXCR2, and CXCR4, has functional interactions in the cytosol, and is reported to be a nuclease. There is a solvent channel down its 3-fold axis with a recently identified gating residue as an allosteric site important for regulating, to different extents, the enzymatic activity and CD74 binding and signaling. In this study we explore the consequence of converting the allosteric residue Tyr99 to cysteine (Y99C) and characterize its crystallographic structure, NMR dynamics, stability, CD74 function, and enzymatic activity. In addition to the homotrimeric variant, we develop strategies for expressing and purifying a heterotrimeric variant consisting of mixed wild type and Y99C for characterization of the allosteric site to provide more insight.

2.
J Lipid Res ; 55(6): 1052-65, 2014 06.
Article in English | MEDLINE | ID: mdl-24771867

ABSTRACT

Thyroid hormone responsive protein Spot 14 has been consistently associated with de novo fatty acid synthesis activity in multiple tissues, including the lactating mammary gland, which synthesizes large quantities of medium chain fatty acids (MCFAs) exclusively via FASN. However, the molecular function of Spot14 remains undefined during lactation. Spot14-null mice produce milk deficient in total triglyceride and de novo MCFA that does not sustain optimal neonatal growth. The lactation defect was rescued by provision of a high fat diet to the lactating dam. Transgenic mice overexpressing Spot14 in mammary epithelium produced total milk fat equivalent to controls, but with significantly greater MCFA. Spot14-null dams have no diminution of metabolic gene expression, enzyme protein levels, or intermediate metabolites that accounts for impaired de novo MCFA. When [(13)C] fatty acid products were quantified in vitro using crude cytosolic lysates, native FASN activity was 1.6-fold greater in control relative to Spot14-null lysates, and add back of Spot14 partially restored activity. Recombinant FASN catalysis increased 1.4-fold and C = 14:0 yield was enhanced 4-fold in vitro following addition of Spot14. These findings implicate Spot14 as a direct protein enhancer of FASN catalysis in the mammary gland during lactation when maximal MCFA production is needed.


Subject(s)
Fatty Acid Synthase, Type I/metabolism , Lactation/physiology , Mammary Glands, Animal/metabolism , Nuclear Proteins/metabolism , Transcription Factors/metabolism , Animals , Catalysis , Fatty Acid Synthase, Type I/genetics , Female , Mice , Mice, Mutant Strains , Nuclear Proteins/genetics , Transcription Factors/genetics
3.
RNA ; 14(6): 1026-36, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18426919

ABSTRACT

Ribonuclease L (RNase L) is a latent endoribonuclease in an evolutionarily ancient interferon-regulated dsRNA-activated antiviral pathway. 2'-5' oligoadenylate (2-5A), the product of dsRNA-activated oligoadenylate synthetases (OASes), binds to ankyrin repeats near the amino terminus of RNase L, initiating a series of conformational changes that result in the activation of the endoribonuclease. A phylogenetically conserved RNA structure within group C enteroviruses inhibits the endoribonuclease activity of RNase L. In this study we report the mechanism by which group C enterovirus RNA inhibits RNase L. Viral RNA did not affect 2-5A binding to RNase L. Rather, the viral RNA inhibited the endoribonuclease domain. We used purified RNase L, purified 2-5A, and an RNA substrate with a 5' fluorophore and 3' quencher in FRET assays to measure inhibition of RNase L activity by the viral RNA. The group C enterovirus RNA was a competitive inhibitor of the endoribonuclease with a K(i) of 34 nM. Consistent with the kinetic profile of a competitive inhibitor, the viral RNA inhibited the constitutively active endoribonuclease domain of RNase L. We call this viral RNA the RNase L competitive inhibitor RNA (RNase L ciRNA).


Subject(s)
Endoribonucleases/antagonists & inhibitors , Enterovirus C, Human/metabolism , RNA, Viral/metabolism , Adenine Nucleotides/chemistry , Adenine Nucleotides/metabolism , Adenine Nucleotides/pharmacology , Base Sequence , Endoribonucleases/metabolism , Enterovirus C, Human/genetics , Enterovirus C, Human/immunology , Fluorescence Resonance Energy Transfer , Humans , Kinetics , Molecular Sequence Data , Mutation , Nucleic Acid Conformation , Oligoribonucleotides/chemistry , Oligoribonucleotides/metabolism , Oligoribonucleotides/pharmacology , Poliovirus/genetics , Protein Structure, Tertiary , RNA, Viral/genetics , RNA, Viral/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...